TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females, aged 18 to 65 years, inclusive, at time of informed consent~* Able to understand and comply with the protocol~* Must be English or French speaking~* At the investigator's opinion, must be willing and able to perform self-injections into the right and left thighs with the single-use autoinjector~Exclusion Criteria:~* Abnormal screening blood tests determined to be clinically significant by the Investigator~* Treatment with any systemic anticoagulant within the previous 30 days~* Treatment with aspirin within the previous 7 days or nonsteroidal anti-inflammatory drugs (NSAIDs) within the previous 3 days~* History of severe allergic or anaphylactic reactions~* History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, pyschiatric, renal, and/or other major disease including bleeding disorders~* Current enrollment in any other investigational study~* Female subjects who are currently pregnant~* History of alcohol or substance abuse or a positive drug screening test on day 1~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- All subjects to self-administer 4 IM injections (Type: EXPERIMENTAL): Subjects will be recruited and stratified into BMI groups: \<18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and \>30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged \> 18 years old~* HIV-1 positive~* Eligible for antiretroviral treatment with CD4 T cell count \< 50 cells/μl~* BMI \< 18~Exclusion Criteria:~* Patients with smear-positive pulmonary TB~* Patients who fulfill the diagnostic criteria for smear-negative pulmonary or extrapulmonary TB (http://www.who.int/tb/publications/2006/tbhiv_recommendations.pdf ).~* Previous TB treatment (history of TB medication for \> 1 month~* History of using antiretroviral drugs~* Symptomatic known underlying liver disease or transaminases \> 5x upper limit of normal~* Known or suspected drug resistance to more than one first-line TB drug according to WHO criteria but excluding HIV infection (e.g. household contacts of MDRTB patients)~* Pregnant or breast-feeding~* Patients with cryptococcal meningitis (CrAG positive with neurologic symptoms)~* Patients with other severe (opportunistic) disease such as disseminated KS, malignant lymphoma, toxoplasmosis who may not be able to tolerate anti-TB medication or require other specific therapy~* Patients with danger signs (respiratory rate \> 30 per minute, heart rate \> 120bpm, temperature \> 39oC, and unable to ambulate)~* Taking other potentially life-saving medications (e.g. for other OIs, or immunosuppressants) that are incompatible with anti-TB chemotherapy or ART~* Unable to swallow TB medications~* Unable to follow-up at the clinic for regularly scheduled follow-up (e.g. too far from clinic)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empiric TB treatment (Type: EXPERIMENTAL): Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
- ART only arm (Type: ACTIVE_COMPARATOR): ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Guided Radiofrequency Ablation Using the CARTO® 3 and NavX™ Systems for the Treatment of Paroxysmal Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients referred for a first radiofrequency ablation procedure for treatment of paroxysmal atrial fibrillation (AF episodes that last less than 30 days and are not terminated via cardioversion) and who are considered eligible for treatment by the physician.~Exclusion Criteria:~* There are no study specific exclusion criteria for this observational study. The exclusion criteria will be conditions that, in the physicians opinion, preclude an RF ablation procedure because the procedure risks outweigh any potential benefits for the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carto 3 (Type: None): Those subjects whose cases use the CARTO 3 EP Navigation System.
- NAVX (Type: None): Those subjects whose cases use the NAVX(TM) EP Navigational System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (condensed):~* Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at least 3 prior lines of therapy~* Measurable disease activity as indicated by serum or urine M-protein, serum free light chain, biopsy-proven plasmacytoma, \>5% bone marrow plasma cells.~* Adequate vital organ function as indicated by ANC (\>1000/uL), platelet count (\>50,000/uL), hemoglobin (\>8 g/dL), serum ALT and AST (each \<3.0 x upper limit of normal), total bilirubin (\<2 mg/dL), creatinine clearance (\>30 mL/min), and cardiac ejection fraction (\>45%)~Exclusion Criteria (condensed):~NOTE: Prior anti-BCMA or CAR-T therapy is NOT exclusionary~* Active plasma cell leukemia~* Pregnant or lactating~* Active, uncontrolled infection~* Active and severe auto-immune disease~* Active arrhythmia, or obstructive or restrictive pulmonary disease~* Central nervous system disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Descartes-08 plus fludarabine/cyclophosphamide pretreat (Type: EXPERIMENTAL): Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Pre-operative Counseling in the Surgical Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* General surgical patients who will undergo same-day laparoscopic ventral hernia, inguinal hernia, and gallbladder surgery at Howard County General Hospital with the general surgery practice at Johns Hopkins Community Physicians.~Exclusion Criteria:~* Patients less than 18 years of age~* Adults who lack the capacity to consent~* Pregnant women~* Prisoners~* Non-English speakers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control arm (Type: NO_INTERVENTION): All subjects in the control arm will receive the current preoperative and post operative instructions.
- 'education booklet' arm (Type: EXPERIMENTAL): All subjects in the 'education booklet' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery
- 'education booklet and preoperative' arm (Type: EXPERIMENTAL): All subjects in the 'education booklet and preoperative' arm will receive the current standard Johns Hopkins Community Physicians Surgery packet and the Patient Information Booklet, specific to participants' surgery. Those subjects randomized to the 'education booklet and preoperative' arm will receive a pre-operative phone call by the research study's lead nurse, Catherine Davidson, approximately 1 week after participants enroll in the study. She will review pre-operative and post-operative guidelines pertinent to participants' operative as outlined in the patient information booklet. The amount of time (in minutes) that this phone call takes will be recorded in an excel file sheet.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipients of primary liver (cadaver/liver, whole/segmental) transplants 5- 30 years old.~* Rejection-free post-transplant course for at least 3 months~* Renal dysfunction (15% decrease in age-adjusted calculated creatinine clearance)~* Hypertension requiring anti-hypertensive mediations.~* Informed consent.~* Weight ≥15 kg.~Exclusion Criteria:~* Rejection or infections within 3 months of enrollment.~* Intent to continue TAC~* Active participation in ongoing studies of immunosuppressive agents.~* Lack of informed consent.~* Pregnant or breast feeding~* HIV positive

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Spinal Cord Compression Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (\> 18 years old) with histopathologically confirmed cancer~* Patients unable to ambulate independently due to paraparesis or paraplegia from malignant epidural spinal cord compression (categories 2, 3, 4 in Appendix B)~* Radiotherapy offered for treatment of cord compression using 2000cGy in 5 fractions~* Informed consent signed~* Females subjects must be post-menopausal or surgically incapable of childbearing potential, must be practicing an acceptable method of birth control (i.e., hormonal contraceptives, intrauterine device or barrier and spermicide)~Exclusion Criteria:~* Uncontrolled hypertension (systolic pressure \> 160 mmHg, diastolic \> 100 mmHg) or unstable cardiovascular disease~* Previous DVT/PE or arterial embolic event~* Patients with a Hb \> 120 g/L or Hct \> 40% (for both males \& females)~* Patients with potentially curable disease~* Patients with life expectancy \< 3 months~* Patients who have received RT that would overlap with the planned treatment field~* Contraindications for MRI scan~* Women who are pregnant, or who intend to become pregnant, or who are nursing~* Patients with known brain metastases; those with a primary diagnosis of melanoma will require confirmation by CT or MRI~* Patients with a history of poorly controlled seizure disorder~* Patients with a known hypersensitivity to mammalian cell-derived products or albumin~* Patients who cannot receive adequate antithrombotic treatment, who have a hypersensitivity to the active antithrombotic substance or any of the product's excipients~* Patients who have participated in another investigational device or drug trial(s), or is receiving other investigational agent(s) within the previous 30 days~* Patients requiring neurosurgical decompression for the malignant spinal cord compression

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any person referred to the Hahnemann University Hospital Electrophysiology Laboratory for a clinically indicated ICD implant~Exclusion Criteria:~* Any person under the age of 18 years~* Inability to give an informed consent~* Allergy to lidocaine~* Receiving lidocaine treatment for pain or arrhythmia~* Contraindication for DFT testing~* Not consenting for DFT testing~* Receiving energy other than 10-12.5 joules as initial DFT test~* Implant of ICD on the right side~* DFT not planned to be performed during ICD implant~* Epicardial placement of ICD leads~* Use of single coil ICD lead~* Subpectoral ICD implantation~* Cephalic cutdown used for central venous access~* Require more than 3mg/kg of 1% SQ lidocaine for local anesthesia~* Pregnant women or prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: EXPERIMENTAL): treatment arm
- Saline (Type: PLACEBO_COMPARATOR): placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: EuroPainClinics® Study IV (Prospective Observational Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergo Endoscopic rhizotomy therapy~Exclusion Criteria:~* No

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- One side endoscopic rhizotomy (Type: None): Endoscopic rhizotomy will be provided only on one back side according pain
- Both sides endoscopic rhizotomy (Type: None): Endoscopic rhizotomy will be provided on both back sides according pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Immediate Skin-to-Skin Contact After Vaginal Birth in Vigorous Late-Preterm Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singletons born 35 0/7 to 36 6/7 weeks GA via vaginal delivery~* Vigorous - crying, good respiratory effort, good tone~* No major congenital malformation~Exclusion Criteria:~* Neonates born \< 35 weeks GA~* Non-vigorous or needing resuscitation soon after birth~* Known major congenital malformation~* Maternal sedation or if clinically unstable per Labor \& Delivery team

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Skin Group (Type: EXPERIMENTAL): Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
- Warmer Group (Type: ACTIVE_COMPARATOR): Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Individuals who received full vaccination with any authorized COVID-19 vaccine and decided to receive a booster vaccination as recommended by national guidelines. -~Exclusion Criteria:~1. Presence of diseases or therapies that are likely to interfere with the immune response to booster vaccination.~2. Any contraindications to the vaccine planned to receive as listed in the product characteristics.~3. Lack of willingness to undergo serial blood draws and attend follow-up appointments.~4. Having already received a third (booster) vaccination with any COVID-19 vaccine.~5. Women who are pregnant or breastfeeding.~6. Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent) -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- blood and saliva sampling (Type: None): blood and saliva samples will be taken

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the RNA Signature of Rheumatoid Arthritis From Synovium and Whole Blood

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Adult men and non-pregnant, non-lactating women between 18 and 75 years of age. Sexually active females must be of either non-childbearing potential or willing to comply with the contraceptive requirements~* Body weight greater \>40 kg and \<120 kg with a body mass index (BMI) between 19-31 kg/m2~* Clinical history of rheumatoid arthritis as defined by ACR criteria~* Negative urine pregnancy test for women of child bearing age (except those with documented proof of hysterectomy or bilateral oophorectomy)~For populations B and C only~* Currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as their only DMARD (no changes in dosing regimen for 4 weeks prior to screening).~Exclusion criteria~* History of an acute illness within 2 weeks prior to the study~* History of drug abuse within 2 years~* Donation of blood in excess of 500 mL within 56 days prior to the first dose of study medication~For group A only~* Prior treatment with disease modifying anti-rheumatic agents or biologicals.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Naive patients (Type: None): 12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
- Patients in remission (Type: None): 6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
- Patients still have active disease (Type: None): 12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children ages 2 years to 7 years who present as patients to the Pediatric Emergency Department at Banner University Medical Center Tucson Campus~* Body weight of 20kg or less (actual, estimated, or measured)~* NPO for four hours or more~* Undergoing various procedures, which are deemed by the treating provider to require procedural sedation for the completion of the procedure.~Exclusion Criteria:~* Discretion of parents~* Discretion of provider~* Body weight greater than 20kg (actual, estimated, or measured)~* Starting Aldrete score \<9/10~* Known or suspected psychosis~* Known or suspected central nervous system mass, abnormalities, hydrocephalus, or other condition that would suggest elevated pre-anesthetic cerebrospinal fluid pressure~* Significant elevation in blood pressure~* Known hypersensitivity to ketamine~* Non-English or Spanish speaking

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal ketamine arm (Type: EXPERIMENTAL): 10mg/kg intranasal ketamine administered one time

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy